Inside the investor’s mind: What fundable companies look like in 2026

As capital deployment becomes more selective, understanding investor expectations is essential for biotech leaders seeking funding. This discussion brings together leading VCs to dissect how decision criteria have evolved, what defines a “fundable” company in 2026, and how scientific, regulatory, and commercial factors intersect to shape valuation and deal momentum.

Key takeaways 

• Define the scientific and operational milestones investors expect before committing capital 

• Examine how early human data and translational proof influence investor confidence 

• Assess how manufacturing readiness and scalability impact funding decisions 

• Explore the role of regulatory clarity and reimbursement strategy in determining company value 

• Identify practical steps biotech founders can take to align with investor priorities